Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
Warning: file_get_contents(http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=21183762&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 445
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Use of low-molecular-weight heparins during percutaneous coronary intervention Martin JL; Slepian MJ Invasive Cardiol 2011[Jan]; 23 (1): 1-8Patients with acute coronary syndromes (ACS) may transition to percutaneous coronary intervention (PCI) after an initial phase of medical management that includes anticoagulation. When patients come to the catheterization laboratory, it is important to consider previously received anticoagulation. Enoxaparin has emerged as a more effective, yet simple, agent for use in the emergency room or upon initial encounter of the ACS patient. However, there may be uncertainty among physicians on the adequacy and way to use anticoagulation in the transition to the catheterization laboratory. Recently, new data have emerged on the use of enoxaparin in the catheterization laboratory. Dosing schedules based on pharmacodynamic and clinical data offer a seamless transition for enoxaparin from the medical management phase to PCI. In this paper, the pharmacokinetics of enoxaparin are reviewed and recommendations for anticoagulant regimens provided based upon the timing of presentation and pre-catheterization dosing.|*Angioplasty, Balloon, Coronary[MESH]|Acute Coronary Syndrome/*therapy[MESH]|Animals[MESH]|Anticoagulants/administration & dosage/pharmacokinetics/*pharmacology/therapeutic use[MESH]|Cardiac Catheterization[MESH]|Dose-Response Relationship, Drug[MESH]|Emergency Medical Services[MESH]|Enoxaparin/administration & dosage/pharmacokinetics/*pharmacology/therapeutic use[MESH]|Humans[MESH]|Injections, Subcutaneous[MESH]|Kidney/drug effects[MESH]|Myocardial Infarction/therapy[MESH]|Randomized Controlled Trials as Topic[MESH]|Thrombolytic Therapy/*methods[MESH] |
